{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:28:26Z","timestamp":1762543706145,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Glutamate carboxypeptidase-II (GCP-II), a zinc metalloenzyme that resides in cell membrane, has been reported as overexpressed in the neovasculature of ovarian cancers. The study objective was to determine whether GCP-II targeted imaging with <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT can detect disease sites in women with advanced high-grade serous ovarian cancer (HGSOC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Twenty treatment-na\u00efve women with advanced HGSOC were recruited (median age 60 years). Prior to commencing therapy (primary cytoreductive surgery [n=9] or neoadjuvant chemotherapy [n=11]), subjects underwent routine staging with contrast-enhanced abdominopelvic CT (=CT), followed by <jats:sup>18<\/jats:sup>F-DCFPyL PET\/CT (=PET). CT and PET were reported independently using a standardized reporting template assessing 25 sites. The performance of PET was compared to CT in all subjects and to surgery and surgical histopathology in 9 patients who underwent primary cytoreductive surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 25 sites assessed in 20 patients, CT detected disease in 292\/500 (58.4%) locations and PET detected disease in 171\/500 (34.2%). Compared to CT the sensitivity (95% CI) of PET to detect disease in the upper abdomen, the gastrointestinal tract or the peritoneum was 0.29 (0.20,0.40), 0.21 (0.11,0.33) and 0.74 (0.64,0.82), respectively. In the surgical cohort, 220 sites in 9 patients were evaluated. The sensitivity and specificity of CT and PET were 0.85 versus 0.54 (p&amp;lt;0.001) and 0.73 versus 0.93 (p&amp;lt;0.001), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although <jats:sup>18<\/jats:sup>F-DCFPyL has higher specificity than CT in detecting advanced HGSOC tumor sites, it detects less disease sites than CT, especially in the upper abdomen and along the gastrointestinal tract, likely limiting its clinical utility.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>ClinicalTrials.gov<\/jats:uri>, NCT03811899.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1025475","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T04:52:24Z","timestamp":1665636744000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["18F-DCFPyL PET\/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study"],"prefix":"10.3389","volume":"12","author":[{"given":"Ur","family":"Metser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshini","family":"Kulanthaivelu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Avery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Hussey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Veit-Haibach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liat","family":"Hogen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: Epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int J Womens Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Montz FJ survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041125","article-title":"Secondary surgical cytoreduction for advanced ovarian carcinoma","volume":"351","author":"Rose","year":"2004","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20376","article-title":"The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian cancer","volume":"101","author":"Dowdy","year":"2004","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31822925c0","article-title":"Identification and quantification of peritoneal metastases in patients with ovarian cancer with multidetector computed tomography: Correlation with surgery and surgical outcome","volume":"21","author":"Metser","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/j.ejrad.2010.07.013","article-title":"FDG-PET\/CT in advanced ovarian cancer staging: Value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy","volume":"80","author":"De Iaco","year":"2011","journal-title":"Eur J Radiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1102\/1470-7330.2001.002","article-title":"Detection of peritoneal metastases","volume":"1","author":"Healy","year":"2001","journal-title":"Cancer Imaging"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e98","article-title":"Performance of pre-treatment  18F-fluorodeoxyglucose positron emission tomography\/computed tomography for detecting metastasis in ovarian cancer: A systematic review and meta-analysis","volume":"29","author":"Han","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2016.08.006","article-title":"Use of (18)F-FDG PET\/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec","volume":"85","author":"Lopez-Lopez","year":"2016","journal-title":"A pending issue. Eur J Radiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.211824","article-title":"Effect of 18F-DCFPyL PET\/CT on the management of patients with recurrent prostate cancer: Results of a prospective multicenter registry trial","volume":"303","author":"Metser","year":"2022","journal-title":"Radiology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.196683","article-title":"Treatment outcomes from 68Ga-PSMA PET\/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: Prognostic value of a negative PSMA PET","volume":"58","author":"Emmett","year":"2017","journal-title":"J Nucl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: Results of an Australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.190827","article-title":"68Ga-PSMA-11 PET\/CT interobserver agreement for prostate cancer assessments: An international multicenter prospective study","volume":"58","author":"Fendler","year":"2017","journal-title":"J Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13397","article-title":"(68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment","volume":"117","author":"van Leeuwen","year":"2016","journal-title":"BJU Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.212233","article-title":"Detection efficacy of [18F]PSMA-1007 PET\/CT in 251 patients with biochemical recurrence after radical prostatectomy","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.212563","article-title":"Outcome after PSMA PET\/CT based salvage radiotherapy in patients with biochemical recurrenceafter radical prostatectomy: A bi-institutional retrospective analysis","volume":"60","author":"Schmidt-Hegemann","year":"2019","journal-title":"J Nucl Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.urology.2017.06.015","article-title":"Prostate cancer local recurrence detected with both 18F-fluciclovine and PSMA-targeted 18F-DCFPyL PET\/CT","volume":"107","author":"Gorin","year":"2017","journal-title":"Urology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1357","article-title":"2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer","volume":"17","author":"Chen","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-015-0866-0","article-title":"Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer","volume":"17","author":"Dietlein","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.211836","article-title":"Impact of 18F-DCFPyL PET on staging and treatment of unfavorable intermediate or high-risk prostate cancer","volume":"304","author":"Basso Dias","year":"2022","journal-title":"Radiology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000297","article-title":"Prostate-specific membrane antigen (PSMA) expression in the neovasculature of gynecologic malignancies: Implications for PSMA-targeted therapy","volume":"25","author":"Wernicke","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1148\/rg.326125511","article-title":"Ovarian carcinomatosis: How the radiologist can help plan the surgical approach","volume":"32","author":"Nougaret","year":"2012","journal-title":"RadioGraphics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"B26","first-page":"45","volume-title":"Modelling binary data, 2nd ed","author":"Collett","year":"1999"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780111108","article-title":"Sensitivity and specificity for correlated observations","volume":"11","author":"Smith","year":"1992","journal-title":"Stat Med"},{"key":"B28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/0471249688","volume-title":"Categorical data analysis, 2nd ed","author":"Agresti","year":"2002"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13550-021-00756-z","article-title":"A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers","author":"Aide","year":"2021","journal-title":"EJNMMI Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","article-title":"Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III\/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan clinical oncology group study JCOG0602","volume":"64","author":"Onda","year":"2016","journal-title":"Eur J Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.21037\/atm-20-1620","article-title":"Upfront debulking surgery for high-grade serous ovarian carcinoma: Current evidence","volume":"8","author":"Tsonis","year":"2020","journal-title":"Ann Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1025475\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T04:52:26Z","timestamp":1665636746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1025475\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":34,"alternative-id":["10.3389\/fonc.2022.1025475"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1025475","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"article-number":"1025475"}}